431 related articles for article (PubMed ID: 25490118)
1. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Ballinger AE; Palmer SC; Nistor I; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2014; 2014(12):CD006254. PubMed ID: 25490118
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
3. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
[TBL] [Abstract][Full Text] [Related]
4. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials.
Palmer SC; Nistor I; Craig JC; Pellegrini F; Messa P; Tonelli M; Covic A; Strippoli GF
PLoS Med; 2013; 10(4):e1001436. PubMed ID: 23637579
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817
[TBL] [Abstract][Full Text] [Related]
7. HMG CoA reductase inhibitors (statins) for kidney transplant recipients.
Palmer SC; Navaneethan SD; Craig JC; Perkovic V; Johnson DW; Nigwekar SU; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD005019. PubMed ID: 24470059
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
9. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
Torres PU
J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
[TBL] [Abstract][Full Text] [Related]
10. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
[TBL] [Abstract][Full Text] [Related]
11. Interventions for preventing bone disease in kidney transplant recipients.
Palmer SC; Chung EY; McGregor DO; Bachmann F; Strippoli GF
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD005015. PubMed ID: 31637698
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
Xu J; Yang Y; Ma L; Fu P; Peng H
Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppressive agents for treating IgA nephropathy.
Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Mealing S; Roome C; Snaith A; D'Souza R; Welch K; Stein K
Health Technol Assess; 2007 May; 11(18):iii, xi-xiii, 1-167. PubMed ID: 17462168
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
[TBL] [Abstract][Full Text] [Related]
16. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001892. PubMed ID: 30284724
[TBL] [Abstract][Full Text] [Related]
17. Low protein diets for non-diabetic adults with chronic kidney disease.
Hahn D; Hodson EM; Fouque D
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD001892. PubMed ID: 33118160
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
[TBL] [Abstract][Full Text] [Related]
19. Antioxidants for adults with chronic kidney disease.
Colombijn JM; Hooft L; Jun M; Webster AC; Bots ML; Verhaar MC; Vernooij RW
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD008176. PubMed ID: 37916745
[TBL] [Abstract][Full Text] [Related]
20. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis.
Zhang Q; Li M; You L; Li H; Ni L; Gu Y; Hao C; Chen J
PLoS One; 2012; 7(10):e48070. PubMed ID: 23133549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]